# Anatole Besarab

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anatole-besarab/

## Facts

| Field | Value |
| --- | --- |
| Citations | 13,167 |
| Field | Central Venous Catheters and Hemodialysis |
| h-index | 56 |
| i10-index | 145 |
| Last Known Institution | University of Virginia |
| OpenAlex ID | https://openalex.org/A5073956335 |
| Works | 276 |

## Researcher papers

- [The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin](https://scholariq.org/papers/the-effects-of-normal-as-compared-with-low-hematocrit-values-in-patients-with/)
- [Recommended standards for reports dealing with arteriovenous hemodialysis accesses](https://scholariq.org/papers/recommended-standards-for-reports-dealing-with-arteriovenous-hemodialysis/)
- [The Society for Vascular Surgery: Clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access](https://scholariq.org/papers/the-society-for-vascular-surgery-clinical-practice-guidelines-for-the-surgical/)
- [Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference](https://scholariq.org/papers/iron-management-in-chronic-kidney-disease-conclusions-from-a-kidney-disease/)
- [Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD](https://scholariq.org/papers/oral-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitor-roxadustat-fg-4592/)
- [Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients](https://scholariq.org/papers/randomized-placebo-controlled-dose-ranging-and-pharmacodynamics-study-of/)
- [Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis](https://scholariq.org/papers/utility-of-intra-access-pressure-monitoring-in-detecting-and-correcting-venous/)
- [Optimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients](https://scholariq.org/papers/optimization-of-epoetin-therapy-with-intravenous-iron-therapy-in-hemodialysis/)
- [Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study](https://scholariq.org/papers/roxadustat-fg-4592-versus-epoetin-alfa-for-anemia-in-patients-receiving/)
- [Roxadustat (FG-4592)](https://scholariq.org/papers/roxadustat-fg-4592/)
- [Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study](https://scholariq.org/papers/iron-repletion-is-associated-with-reduction-in-platelet-counts-in-non-dialysis/)
- [Intravenous Iron Dextran as a Component of Anemia Management in Chronic Kidney Disease: A Report of Safety and Efficacy](https://scholariq.org/papers/intravenous-iron-dextran-as-a-component-of-anemia-management-in-chronic-kidney/)

## Researcher topics

- [Central Venous Catheters and Hemodialysis](https://scholariq.org/topics/central-venous-catheters-and-hemodialysis/)
- [Erythropoietin and Anemia Treatment](https://scholariq.org/topics/erythropoietin-and-anemia-treatment/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Vascular Procedures and Complications](https://scholariq.org/topics/vascular-procedures-and-complications/)
- [Iron Metabolism and Disorders](https://scholariq.org/topics/iron-metabolism-and-disorders/)

## Researcher university

- [University of Virginia](https://scholariq.org/institutions/university-of-virginia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.